PT-112 in Subjects With Thymoma and Thymic Carcinoma

Exclusion Criteria

• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to PT-112. Since there is no definitive list of compounds of similar chemical or biologic composition to PT-112, the principal investigator if in doubt, will report known allergies to the pharmacist to make a determination as to whether it is safe to enroll a participant.
• •Concurrent treatment with a non-permitted drug.
• •Concurrent anticancer treatment within 14 days before initiation of study therapy (includes radiotherapy; however, palliative bone-directed radiotherapy is permitted).
• •Major surgery within 14 days before enrollment (excluding prior diagnostic biopsy).
• •Concurrent systemic therapy with immunosuppressive agents within 14 days (or 5 half-lives of a drug, whichever is shorter) before initiation of study therapy.
• •Use of hormonal agents for anti-cancer therapy within 14 days before initiation of study therapy; or use of any investigational drug within 14 days before initiation of study therapy.
• •History of previous malignant disease within the last 2 years with the following exceptions: basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary or follicular thyroid carcinoma, and non-muscle invasive bladder cancer.
• •Active infection requiring systemic therapy or significant acute or chronic infections including, among others:
• •* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
• •* Known history of testing positive for HIV or known acquired immunodeficiency syndrome with a detectable viral load. However, participants with HIV who have an undetectable viral load and are on stable doses of Highly Active Antiretroviral Therapy (HAART) can be screened for the study.
• •Persisting toxicity related to prior therapy (NCI CTCAE v. 5 Grade \> 1) with the exception of, alopecia, sensory neuropathy Grade \<= 2 and hearing loss Grade \<=2.
• •Known alcohol or drug abuse.
• •Uncontrolled intercurrent illness including, but not limited to the following:
• •* Cardiovascular: SYMPTOMATIC congestive heart failure, unstable angina pectoris or cardiac arrhythmia, either active or within the past 6 months
• •* Respiratory: Pneumonitis or Idiopathic pulmonary fibrosis (not radiation-associated fibrosis), either active or within the past 6 months
• •* Gastrointestinal: Immune colitis or inflammatory bowel disease, either active or within the past 6 months
• •* Hematological: Bleeding diathesis or major bleeding events, either active or within the past 6 months
• •* Other: psychiatric illness/social situations that would limit compliance with study requirements, including active suicidal ideation or behavior, either active or within the past 12 months
• •Administration of live vaccines within 4 weeks prior to treatment. COVID-19 vaccines are permitted at screening.